Sponsored by Novartis Medical Affairs | December 30, 2025

DISCLAIMER: The content provided herein is for your background and educational purposes only and may not be altered or further disseminated in any fashion. Please refer to full Prescribing Information.

The SUNSHINE/SUNRISE core and extension trials have demonstrated sustained clinical benefits of secukinumab treatment through 2 years in patients with moderate to severe hidradenitis suppurativa (HS). This post hoc analysis assessed the efficacy and safety of continuous secukinumab treatment through 4 years.

Patients completing the core trials could enter a 4-year extension trial, whereby patients were stratified according to their HS clinical response (HiSCR) status at week 52 (responders [HiSCR-R] or nonresponders [HiSCR-NR]). HiSCR50/75/90/100, mean and percentage change from baseline (cfb) draining tunnel count, and safety outcomes were assessed for patients receiving continuous secukinumab treatment through week 204. Efficacy analyses are reported for HiSCR-R patients and safety analyses are reported for all patients. Data are reported as observed without formal hypothesis testing.

Overall, 172 HiSCR-R patients and 200 HiSCR-NR patients received continuous secukinumab up to week 204. HiSCR-R patients achieved sustained clinical responses through 4 years, with 83.2%, 74.8%, 50.5%, and 40.2% achieving HiSCR50, HiSCR75, HiSCR90, and HiSCR100, respectively, at week 204. Reductions in the mean draining tunnel count in HiSCR-R patients persisted through week 204 (cfb: −35.4% and −68.5% at weeks 16 and 204, respectively).

Continuous secukinumab treatment was well tolerated through week 204 by both HiSCR-R and HiSCR-NR patients.

Secukinumab Indications and Important Safety Considerations

Indications

Secukinumab is a human interleukin-17A antagonist indicated for the treatment of:

• Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy
• Active psoriatic arthritis (PsA) in patients 2 years of age and older
• Adults with active ankylosing spondylitis (AS)
• Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
• Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older
• Adults with moderate to severe hidradenitis suppurativa (HS)

Important Safety Considerations

Contraindications: Serious hypersensitivity to secukinumab or any excipients in secukinumab

Warnings and Precautions:

Infections: Serious infections have occurred. Exercise caution when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue secukinumab until the infection resolves.

Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue secukinumab immediately and initiate appropriate therapy.

Tuberculosis (TB): Prior to initiating treatment with secukinumab, evaluate for TB.

Inflammatory Bowel Disease (IBD): Cases of IBD were observed in clinical trials. Exercise caution when prescribing secukinumab to patients with IBD.

Eczematous Eruptions: Cases of severe eczematous eruptions have occurred in patients receiving secukinumab.

Immunizations: Avoid use of live vaccines in patients treated with secukinumab.

Adverse Reactions: Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. 

This poster was previously presented at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA 2025), Nashville, TN, USA, October 31-November 2, 2025. 

Novartis has paid DermSquared to host this content. Novartis is solely responsible for all the written content within this presentation.

© 2025 Novartis. All rights reserved.

12/25 FA-11569610